Loading viewer...
report
Format: PDF report
This report details the Phase 1/2 clinical trial of OCU400, a potential gene therapy for Retinitis Pigmentosa and Leber Congenital Amaurosis, highlighting its safety and efficacy.
presentation
report
Douglas Emmett
report
CBOE
report
Allseas
report
World Acceptance Corporation